Molecular Partners Ag Stock Today
| MOLN Stock | USD 5.02 0.44 9.61% |
Performance0 of 100
| Odds Of DistressLess than 22
|
Molecular Partners is selling at 5.02 as of the 4th of October 2024; that is 9.61% increase since the beginning of the trading day. The stock's open price was 4.58. Molecular Partners has about a 22 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Molecular Partners AG are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 15th of October 2022 and ending today, the 4th of October 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of June 2021 | Category Healthcare | Classification Health Care |
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland. Molecular Partners operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 33.19 M outstanding shares of which 29.89 K shares are now shorted by private and institutional investors with about 5.83 trading days to cover. More on Molecular Partners AG
Moving together with Molecular Stock
| 0.74 | VALN | Valneva SE ADR | PairCorr |
| 0.78 | DYAI | Dyadic International | PairCorr |
| 0.78 | ERNA | Eterna Therapeutics | PairCorr |
Moving against Molecular Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Molecular Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Swiss Performance Extra, NASDAQ Health Care, Swiss Performance Index, Biotech, Health Management, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMolecular Partners can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Molecular Partners' financial leverage. It provides some insight into what part of Molecular Partners' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Partners AG (MOLN) is traded on NASDAQ Exchange in USA. It is located in Wagistrasse 14, Schlieren, Switzerland, 8952 and employs 161 people. Molecular Partners is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 159.6 M. Molecular Partners conducts business under Biotechnology sector and is part of Health Care industry. The entity has 33.19 M outstanding shares of which 29.89 K shares are now shorted by private and institutional investors with about 5.83 trading days to cover.
Molecular Partners AG currently holds about 267.13 M in cash with (55.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Molecular Partners Probability Of Bankruptcy
Ownership AllocationMolecular Partners maintains a total of 33.19 Million outstanding shares. Roughly 97.41 % of Molecular Partners outstanding shares are held by general public with 2.59 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Molecular Ownership Details
Molecular Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bvf Inc | 2024-06-30 | 443.2 K | |
| Suvretta Capital Management, Llc | 2024-06-30 | 400 K | |
| Old Mission Capital Llc | 2024-06-30 | 10.4 K | |
| Ubs Group Ag | 2024-06-30 | 3.5 K | |
| Tang Capital Management Llc | 2024-06-30 | 2.5 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 367 | |
| Rhumbline Advisers | 2024-06-30 | 269 | |
| Qube Research & Technologies | 2024-06-30 | 16.0 | |
| Susquehanna International Group, Llp | 2024-03-31 | 0.0 | |
| Royal Bank Of Canada | 2024-06-30 | 0.0 | |
| Jpmorgan Chase & Co | 2024-03-31 | 0.0 |
Molecular Partners Historical Income Statement
Molecular Stock Against Markets
Molecular Partners Corporate Management
| Robert Hendriks | Senior Finance | Profile | |
| Alexander Zurcher | COO Board | Profile | |
| Michael Pitzner | Compliance Counsel | Profile | |
| MD MBA | Interim Officer | Profile | |
| Daniel Steiner | Senior Technology | Profile | |
| Anne DVM | Senior Development | Profile |
Additional Information and Resources on Investing in Molecular Stock
When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.07) | Revenue Per Share 0.239 | Quarterly Revenue Growth 2.737 | Return On Assets (0.19) | Return On Equity (0.32) |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.